Min Jeong Park

Min Jeong Park

Auto-generated profile, based on publicly available information

Min Jeong Park

Department of Internal Medicine Korea University Medical Center Guro Hospital Seoul Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2023 in Metabolism
Verified
Journal Article
Closed access
MPMin Jeong Park
Min Jeong Park
KCKyung Mook Choi
Kyung Mook Choi

7 June 2018 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
WZWafik Zaky
Wafik Zaky
SPShekhar S. Patil
Shekhar S. Patil
MPMinjeong Park
Minjeong Park
DLDiane Liu
Diane Liu
WWWei-Lien Wang
Wei-Lien Wang
SKSoumen Khatua
Soumen Khatua

28 October 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
EREun Roh
Eun Roh
ENEunjin Noh
Eunjin Noh
SHSoon Young Hwang
Soon Young Hwang
JKJung A Kim
Jung A Kim
ESEyun Song
Eyun Song
HYHye Jin Yoo
Hye Jin Yoo
Context: Abnormal thyroid function after thyroidectomy and subsequent thyroid-stimulating hormone suppression can have detrimental effects on glucose homeostasis in patients with thyroid cancer. Objective: To investigate whether thyroidectomy increases the risk of type 2 diabetes in patients with thyroid cancer and to explore the association between levothyroxine dosage and type 2 diabetes risk. Methods: A retrospective population-based cohort study using the Korean National Health Insurance database. We included 36 377 thyroid cancer patients without known diabetes who underwent thyroidectomy between 2004 and 2013. Matched subjects with nonthyroid cancer were selected using 1:1 propensity score matching. The main outcome measure was newly developed type 2 diabetes mellitus. Results: Patients with thyroid cancer who underwent thyroidectomy had a higher risk of developing type 2 diabetes mellitus than the matched controls (hazard ratio [HR] 1.43, 95% CI 1.39-1.47). Among patients with thyroid cancer, when the second quartile group (in terms of the mean levothyroxine dosage; 101-127 μg/day) was considered the reference group, the risk of type 2 diabetes mellitus increased in the first quartile (<101 μg/day; HR 1.45, 95% CI 1.36-1.54) and fourth quartile groups (≥150 μg/day; HR 1.37, 95% CI 1.29-1.45); meanwhile, the risk decreased in the third quartile group (128-149 μg/day; HR 0.91, 95% CI 0.85-0.97). Conclusion: Patients with thyroid cancer who underwent thyroidectomy were more likely to develop type 2 diabetes mellitus than the matched controls. There was a U-shaped dose-dependent relationship between the levothyroxine dosage and type 2 diabetes mellitus risk.

31 January 2022 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
MPMin Jeong Park
Min Jeong Park
KCKyung Mook Choi
Kyung Mook Choi
Despite strenuous efforts to reduce cardiovascular disease (CVD) risk by improving cardiometabolic risk factors, such as glucose and cholesterol levels, and blood pressure, there is still residual risk even in patients reaching treatment targets. Recently, researchers have begun to focus on the variability of metabolic variables to remove residual risks. Several clinical trials and cohort studies have reported a relationship between the variability of metabolic parameters and CVDs. Herein, we review the literature regarding the effect of metabolic factor variability and CVD risk, and describe possible mechanisms and potential treatment perspectives for reducing cardiometabolic risk factor variability.

8 June 2017 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Open access
PDF file
CCCaiqian Cropper
Caiqian Cropper
AWAshley Woodson
Ashley Woodson
BABanu K. Arun
Banu K. Arun
CBCarlos Barcenas
Carlos Barcenas
JLJennifer Litton
Jennifer Litton
MDMolly Daniels
Molly Daniels
Background: Mutations in the BRCA1 and BRCA2 genes predispose individuals to a significantly elevated risk for breast and ovarian cancers. Identification of these individuals allows for proper screening, management, and testing of at-risk relatives. NCCN has established clinical criteria for recommending BRCA1/2 testing. Patients and Methods: A retrospective chart review of 1,123 patients with breast cancer was performed to evaluate the positive predictive values (PPVs) of 14 individual criteria for predicting BRCA1/2 mutations. Results: Two criteria had PPVs significantly below 10%. Only 2 of 115 patients who were recommended for testing based solely on the criterion of “diagnosed with breast cancer at ≤45 years of age” had pathogenic mutations at a PPV of 1.6% (95% CI, 0.2%–6.0%). Additionally, 0 of 37 individuals who underwent testing based on the criterion, “diagnosed with breast cancer at any age with ≥2 close blood relatives with breast cancer at any age” tested positive (95% CI, 0%–9%). Overall, meeting >1 criterion has a PPV of 12%, whereas meeting only 1 criterion has a PPV of 3.2% (95% CI, 1.6%–5.7%), significantly below 10% (P<.0001) for predicting BRCA1/2 positivity. Conclusions: Patients with breast cancer meeting >1 criterion constitute a population significantly enriched for BRCA1/2 mutations, whereas those meeting only 1 criterion test positive at a rate similar to unselected patients with breast cancer. These data will inform ongoing discussions regarding how to best implement BRCA1/2 genetic testing.

Verified
Journal Article
Open access
PDF file
MPMin Jeong Park
Min Jeong Park
JCJae Hwa Cho
Jae Hwa Cho
YCYoujin Chang
Youjin Chang
JMJae Young Moon
Jae Young Moon
SPSunghoon Park
Sunghoon Park
YLYoung Seok Lee
Young Seok Lee
Noninvasive ventilation (NIV) is useful when managing critically ill patients. However, it is not easy to apply to elderly patients, particularly those with pneumonia, due to the possibility of NIV failure and the increased mortality caused by delayed intubation. In this prospective observational study, we explored whether NIV was appropriate for elderly patients with pneumonia, defined factors that independently predicted NIV failure, and built an optimal model for prediction of such failure. We evaluated 78 patients with a median age of 77 years. A low PaCO2 level, a high heart rate, and the presence of pneumonia were statistically significant independent predictors of NIV failure. The predictive power for NIV failure of Model III (pneumonia, PaCO2 level, and heart rate) was better than that of Model I (pneumonia alone). Considering the improvement in parameters, patients with successful NIV exhibited significantly improved heart rates, arterial pH and PaCO2 levels, and patients with NIV failure exhibited a significantly improved PaCO2 level only. In conclusion, NIV is reasonable to apply to elderly patients with pneumonia, but should be done with caution. For the early identification of NIV failure, the heart rate and arterial blood gas parameters should be monitored within 2 h after NIV commencement.